theophylline monohydrate (Q47495785)

significant drug interaction

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lithium

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vemurafenib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

subject has role

phosphodiesterase inhibitor

1 reference

5 March 2018

C872

1 reference

UNII

C137DTR5RG

InChI=1S/C7H8N4O2.H2O/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;/h3H,1-2H3,(H,8,9);1H2

25 January 2018

Identifiers

InChI

1 reference

25 January 2018

1 reference

25 January 2018

2 references

https://commonchemistry.cas.org/detail?cas_rn=5967-84-0

25 January 2018

6 April 2021

1 reference

25 January 2018

2 references

25 January 2018

SureChEMBL ID

SCHEMBL387338

2 references

based on heuristic

inferred from InChIKey

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

1 reference

2 references

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.110.629

ECHA Substance Infocard ID

27 December 2018

title

1H-Purine-2,6-dione, 3,9-dihydro-1,3-dimethyl-, hydrate (1:1) (English)

quotation

CAS no.: 5967-84-0 (English)

100.110.629

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.110.629

27 December 2018

title

1H-Purine-2,6-dione, 3,9-dihydro-1,3-dimethyl-, hydrate (1:1) (English)

quotation

CAS no.: 5967-84-0 (English)

RxNorm ID

10438

1 reference

25 January 2018

2 references

UNII

C137DTR5RG

25 January 2018